A randomized, open-label study of the effect of MabThera, with and without fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia.

Trial Profile

A randomized, open-label study of the effect of MabThera, with and without fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 29 Aug 2016 Results (n=554) of this and other trial (CLL10) published in the Journal of Clinical Oncology (2016).
    • 08 Dec 2015 Results (pooled analysis of CLL8 and CLL10 studies) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 635).
    • 20 Oct 2015 Updated long term follow-up results published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top